Selected article for: "continuous variable and hazard ratio"

Author: Xia, Leilei; Talwar, Ruchika; Chelluri, Raju R.; Guzzo, Thomas J.; Lee, Daniel J.
Title: Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer
  • Cord-id: n77kyjtv
  • Document date: 2020_12_8
  • ID: n77kyjtv
    Snippet: IMPORTANCE: There is a lack of data evaluating the association of surgical delay time (SDT) with outcomes in patients with localized, high-risk prostate cancer. OBJECTIVE: To investigate the association of SDT of radical prostatectomy and final pathological and survival outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the US National Cancer Database (NCDB) and identified all patients with clinically localized (cT1-2cN0cM0) high-risk prostate adenocarcinoma diagnosed
    Document: IMPORTANCE: There is a lack of data evaluating the association of surgical delay time (SDT) with outcomes in patients with localized, high-risk prostate cancer. OBJECTIVE: To investigate the association of SDT of radical prostatectomy and final pathological and survival outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the US National Cancer Database (NCDB) and identified all patients with clinically localized (cT1-2cN0cM0) high-risk prostate adenocarcinoma diagnosed between 2006 and 2016 who underwent radical prostatectomy. Data analyses were performed from April 1 to April 12, 2020. EXPOSURES: SDT was defined as the number of days between the initial cancer diagnosis and radical prostatectomy. SDT was categorized into 5 groups: 31 to 60, 61 to 90, 91 to 120, 121 to 150, and 151 to 180 days. MAIN OUTCOMES AND MEASURES: The primary outcomes were predetermined as adverse pathological outcomes after radical prostatectomy, including pT3-T4 disease, pN-positive disease, and positive surgical margin. The adverse pathological score (APS) was defined as an accumulated score of the 3 outcomes (0-3). An APS of 2 or higher was considered a separate outcome to capture cases with more aggressive pathological features. The secondary outcome was overall survival. RESULTS: Of the 32 184 patients included in the study, the median (interquartile range) age was 64 (59-68) years, and 25 548 (79.4%) were non-Hispanic White. Compared with an SDT of 31 to 60 days, longer SDTs were not associated with higher risks of having any adverse pathological outcomes (odds ratio [OR], 0.95; 95% CI, 0.80-1.12; P = .53), pT3-T4 disease (OR, 0.99; 95% CI, 0.83-1.17; P = .87), pN-positive disease (OR, 0.79; 95% CI, 0.59-1.06; P = .12), positive surgical margin (OR, 0.88; 95% CI, 0.74-1.05; P = .17), or APS greater than or equal to 2 (OR, 0.90; 95% CI, 0.74-1.05; P = .17). Longer SDT was also not associated with worse overall survival (for SDT of 151-180 days, hazard ratio, 1.12; 95% CI, 0.79-1.59, P = .53). Subgroup analyses performed for patients with very high-risk disease (primary Gleason score 5) and sensitivity analyses with SDT considered as a continuous variable yielded similar results. CONCLUSIONS AND RELEVANCE: In this cohort study of patients who underwent radical prostatectomy within 180 days of diagnosis for high-risk prostate cancer, radical prostatectomy for high-risk prostate cancer could be safely delayed up to 6 months after diagnosis.

    Search related documents:
    Co phrase search for related documents
    • locally advanced and low risk prostate cancer: 1, 2
    • locally advanced and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • locally advanced and lymph node dissection: 1, 2, 3
    • locally advanced and lymph node metastasis: 1, 2, 3
    • locally advanced cancer and logistic regression: 1, 2, 3, 4
    • locally advanced cancer and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • locally advanced cancer and lymph node dissection: 1, 2, 3
    • locally advanced cancer and lymph node metastasis: 1, 2
    • locally advanced disease and logistic regression: 1
    • locally advanced disease and lymph node: 1, 2
    • logistic regression and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • logistic regression and lymph node dissection: 1
    • logistic regression and lymph node metastasis: 1, 2